HC Wainwright Reaffirms “Buy” Rating for Aura Biosciences (NASDAQ:AURA)

Aura Biosciences (NASDAQ:AURA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $22.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 112.97% from the company’s current price.

AURA has been the topic of several other research reports. JMP Securities raised their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Scotiabank lifted their target price on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Finally, BTIG Research raised their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Trading Down 3.0 %

Shares of NASDAQ AURA opened at $10.33 on Thursday. The company has a market cap of $512.47 million, a price-to-earnings ratio of -5.97 and a beta of 0.33. The stock’s 50 day simple moving average is $9.75 and its 200 day simple moving average is $8.50. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. As a group, equities analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the transaction, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at $1,615,340.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CFO Julie B. Feder sold 25,131 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now owns 134,276 shares of the company’s stock, valued at $1,615,340.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 67,259 shares of company stock worth $780,699. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AURA. American International Group Inc. lifted its holdings in shares of Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after buying an additional 3,782 shares during the last quarter. Levin Capital Strategies L.P. lifted its stake in Aura Biosciences by 11.2% in the first quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock valued at $873,000 after acquiring an additional 11,200 shares during the last quarter. Virtu Financial LLC bought a new stake in Aura Biosciences in the first quarter worth approximately $144,000. Bank of New York Mellon Corp increased its stake in shares of Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after purchasing an additional 48,549 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Aura Biosciences by 39.6% during the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.